Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 43.17 1.15% 0.49
ARNA closed up 1.15 percent on Friday, January 18, 2019, on 56 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical ARNA trend table...

Date Alert Name Type % Chg
Jan 16 NR7 Range Contraction -0.94%
Jan 15 180 Bullish Setup Bullish Swing Setup -1.30%
Jan 14 NR7 Range Contraction 3.03%
Jan 14 Overbought Stochastic Strength 3.03%
Jan 14 Down 3 Days in a Row Weakness 3.03%
Jan 11 Overbought Stochastic Strength 0.94%
Jan 10 Stochastic Sell Signal Bearish -1.82%
Jan 10 Upper Bollinger Band Walk Strength -1.82%
Jan 10 Overbought Stochastic Strength -1.82%
Jan 9 Slingshot Bullish Bullish Swing Setup -1.84%

Older signals for ARNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Is ARNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 50.05
52 Week Low 30.0
Average Volume 651,624
200-Day Moving Average 41.1079
50-Day Moving Average 39.939
20-Day Moving Average 40.8645
10-Day Moving Average 43.283
Average True Range 1.9498
ADX 16.13
+DI 22.7961
-DI 18.522
Chandelier Exit (Long, 3 ATRs ) 39.2606
Chandelier Exit (Short, 3 ATRs ) 40.8894
Upper Bollinger Band 46.2526
Lower Bollinger Band 35.4764
Percent B (%b) 0.71
BandWidth 26.370566
MACD Line 1.0663
MACD Signal Line 0.8922
MACD Histogram 0.1741
Fundamentals Value
Market Cap 1.69 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -58.34
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.62
Resistance 3 (R3) 45.61 44.80 45.21
Resistance 2 (R2) 44.80 44.17 44.80 45.07
Resistance 1 (R1) 43.98 43.79 44.39 43.99 44.94
Pivot Point 43.17 43.17 43.37 43.17 43.17
Support 1 (S1) 42.35 42.54 42.76 42.36 41.40
Support 2 (S2) 41.54 42.16 41.54 41.27
Support 3 (S3) 40.72 41.54 41.13
Support 4 (S4) 40.73